| Literature DB >> 35566799 |
Anat Hershko-Klement1, Shaul Raviv2, Luba Nemerovsky2, Tal Rom2, Ayelet Itskovich2, Danit Bakhshi2, Adrian Shulman2, Yehudith Ghetler2.
Abstract
The increased use of vitrified blastocysts has encouraged the development of various criteria for selecting the embryo most likely to implant. Post-thaw assessment methods and timetables vary among investigators. We investigated the predictive value of well-defined measurements of human blastocyst re-expansion, following a fixed incubation period. Post-thaw measurements were taken exactly at 0 and 120 ± 15 min. Minimum and maximum cross-sectional axes were measured. Three groups were defined: Group 1: embryos that continued to shrink by 10 µm or more; group 2: embryos that ranged from -9 to +9 µm; and group 3: re-expansion of 10 µm or more. Patient and morphokinetic data were collected and integrated into the analysis. A total of 115 cases were included. The clinical pregnancy rate for group 1 was 18.9%; group 2, 27%; and group 3, 51.2% (p = 0.007). Pre-thaw morphologic grading and morphokinetic scores of the study groups did not reveal differences. p-values were 0.17 for the pre-thaw morphologic score, 0.54 for KID3, and 0.37 for KID5. The patients' demographic and clinical data were similar. The clinical pregnancy rate correlated with the degree of thawed blastocyst re-expansion measured 2 h after incubation. This standardized measure is suggested as a tool to predict the potential of treatment success before embryo transfer.Entities:
Keywords: blastocyst; expansion; in vitro fertilization; pregnancy rate; vitrification
Year: 2022 PMID: 35566799 PMCID: PMC9101782 DOI: 10.3390/jcm11092673
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241
Figure 1Measurement protocol of thawed blastocysts.
Figure 2Examples of embryonic measurements and grouping criteria.
Figure 3Histogram illustrating changes in size between the two-hour diameter and immediate post-thaw diameter for each of 115 embryos (µm).
Pre-vitrification embryonic data as expressed by expansion score and KID score.
| Study Group * ( | Pre-Freeze Gardner’s Expansion Score | KID Score Day 3 | KID Score | |||
|---|---|---|---|---|---|---|
| 2 | 3 | 4 | 5 | |||
| 1 (37) | 5 (13.5) | 7 (18.9) | 24 (64.9) | 1 (2.7) | 4.27 ± 1.26 | 6.92 ± 1.35 |
| 2 (37) | 8 (21.6) | 10 (27.0) | 17 (45.9) | 2 (5.4) | 4.27 ± 1.17 | 6.48 ± 1.79 |
| 3 (41) | 2 (4.9) | 8 (19.5) | 26 (63.4) | 5 (12.2) | 4.51 ± 0.87 | 6.94 ± 1.62 |
| 0.17 | 0.54 | 0.37 | ||||
Numbers represent mean ± SD or n (%); * Group 1—Shrunk ≥10 µm; group 2—Change between −9 and +9 µm; group 3—re-expansion trend ≥10 µm.
Main demographic, clinical and clinical pregnancy data according to study groups.
| Study Group* ( | Age (at | N Oocytes Aspirated | Endometrial Lining, mm | Fertilization Method (%) | Clinical Pregnancy | |
|---|---|---|---|---|---|---|
| IVF | ICSI | |||||
| 1 (37) | 33.65 ± 6.01 | 12.38 ± 6.08 | 8.6 ± 2.1 | 54.1 | 45.9 | 7 (18.9%) |
| 2 (37) | 32.89 ± 5.04 | 13.89 ± 7.12 | 9.4 ± 1.9 | 67.6 | 32.4 | 10 (27.0%) |
| 3 (41) | 33.63 ± 6.07 | 14.22 ± 8.31 | 9.1 ± 1.5 | 57.9 | 42.1 | 21 (51.2%) |
| 0.88 | 0.50 | 0.16 | 0.49 | 0.007 | ||
Numbers represent mean ± SD or n (%); * Group 1—Shrinking ≥10 µm; group 2—Change between −9 and +9 to µm; group 3—re-expansion trend ≥10 µm.
Indications for infertility treatment.
| Study Group * ( | Infertility Treatment Indication | |||||
|---|---|---|---|---|---|---|
| Male | Ovulatory Dysfunction | Mechanical | Unexplained | Uterine | Other | |
| 1 (37) | 8 (21.6) | 6 (16.2) | 6 (16.2) | 8 (21.6) | 1 (2.7) | 8 (21.6) |
| 2 (37) | 11 (29.7) | 5 (13.5) | 10 (27.0) | 5 (13.5) | 0 (0.0) | 6 (16.2) |
| 3 (41) | 14 (34.1) | 4 (9.8) | 5 (12.2) | 7 (17.1) | 2 (4.9) | 9 (22.0) |
Numbers represent n (%); * Group 1—Shrinking ≥10 µm; group 2—Change between −9 and +9 µm; group 3—re-expansion trend ≥10 µm.
Clinical pregnancy rate according to age at oocyte retrieval.
| Study Group * | Age < 35 Years | Age ≥ 35 Years |
|---|---|---|
| Clinical Pregnancy | Clinical Pregnancy | |
| Group 1 | 20 (25) | 17 (11.8) |
| Group 2 | 23 (34.8) | 14 (14.3) |
| Group 3 | 21 (52.4) | 20 (50.0) |
| 0.07 | 0.009 |
* Group 1—Shrunk ≥10 µm; group 2—Change between −9 and +9 µm; group 3—re-expansion trend ≥10 µm.